< PrevNext > 98. Astrazeneca Cambridge, England Share 2018 U.S.-Booked Air Volume: $47 millionConsolidated Global TMC: BCDGlobal pharmaceutical and biopharmaceutical company Astrazeneca finished 2018 strong, CEO Pascal Soriot telling investors the company had “returned to growth” with a 4 percent increase in product sales for the year to $21 million. Revenue totaled $22 million. The company closed two facilities in Colorado, which could curtail domestic travel. On the other hand, U.S. product sales rose 11 percent, while sales to China increased 28 percent, which could translate into increased Asia/Pacific travel. The company, which has more than 60,000 employees worldwide, spent the latter half of this decade bringing its global corporate travel program under BCD Travel, including consolidating policies and programs in more than 75 countries.